Investor Relations

By helping our clients to consistently outperform and build a strong foundation for the future, Cowen aims to deliver long-term value for our shareholders.

FINANCIALS

Explore our SEC filings, corporate governance information and other shareholder information. Take a moment to read our latest Annual Report.

Stay up to date

GET IN TOUCH

Cowen Investor inquiries will be routed to Steve Lasota, CFO

Stock Quote

COWN

Exchange NASDAQ (USD)
Price $38.67
Change +0.07 / +0.18%
Volume 421,341

Data as of 10/06/2022 4:00 PM UTC.
Minimum 15 minute delay.

News

ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases

Read the article “ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases”
News

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

Read the article “Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals”
News

Cowen Digital Expands Institutional Team with Crypto-Native Hires

Read the article “Cowen Digital Expands Institutional Team with Crypto-Native Hires”